SU1342509A1 - Method of treatment of urogenital chlamidioses - Google Patents
Method of treatment of urogenital chlamidioses Download PDFInfo
- Publication number
- SU1342509A1 SU1342509A1 SU864079884A SU4079884A SU1342509A1 SU 1342509 A1 SU1342509 A1 SU 1342509A1 SU 864079884 A SU864079884 A SU 864079884A SU 4079884 A SU4079884 A SU 4079884A SU 1342509 A1 SU1342509 A1 SU 1342509A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- patient
- avelysin
- streptokinase
- antibiotics
- urogenital
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 229960005202 streptokinase Drugs 0.000 claims abstract description 11
- 108010023197 Streptokinase Proteins 0.000 claims abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 6
- 230000003115 biocidal effect Effects 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 102000013566 Plasminogen Human genes 0.000 claims description 2
- 108010051456 Plasminogen Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000004018 waxing Methods 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000002823 anti-activator Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Дл излечени антибиотикорезистёнтных форм восцалени и предуцреждени рецидивов провод т комплексную терапию стрептокиназой совместно с антибиотиками. 00 г сд о соTo cure antibiotic-resistant forms of waxing and the prevention of relapse, complex therapy with streptokinase together with antibiotics is carried out. 00 g cd about with
Description
113425092113425092
Изобретение относитс к медицине, Пример 2, Больному 3,,The invention relates to medicine, Example 2, to Patient 3,
в частности к урологии,35 лет, на основании субъективных,in particular, to urology, 35 years old, on the basis of subjective,
Целью изобретени вл етс извле- . микробиологических и объективныхThe aim of the invention is to retrieve. microbiological and objective
чение антибиотикоре8истентных формданных повторного клинического исвоспалени и предупреждени рецидивовследовани диагностирован мочеполоблагодар проведению комплексной те-вой хламидиоз, антибиотикорезистентрапии стрептокиназой совместно с ан- на форма. До вливани стептокиназыAntibiotics resistant formidan recurrent clinical resuscitation and prevention of recurrence were diagnosed with a genitourinary complex chlamydia, antibiotics resistivity with streptokinase together with anna form. Before the infusion of steptokinase
тибиотиками.у больного вы влены в анализах следуПример 1. Больной Г., Q ющие отклонени : в моче белок 0,02%,Tibiotics. The patient was identified in the following tests: Example 1. Patient G., Q ia deviations: 0.02% protein in urine,
30 лет, боли в мочеиспускательном ка-слизь ++; активность антиактиватора30 years, pain in the urethra ++; antiactivator activity
нале, в суставах и частные глазныеплазминогена 2% (так как зона лизисаnale, in the joints and private ophthalmic plasminogen 2% (since the lysis zone
боли (синдром Рейтера).на фибриновых пластинах 1225 кв.мм).pain (Reiter's syndrome). on fibrin plates 1225 sq. mm).
Диагностицирована антибиотикоре-Титр антител к стрептокиназе 100 зистентна форма мочеполового хлами- 15 антистрептокиназных единиц в 1 млAntibiotics are diagnosed-Antibody titer to streptokinase 100 resistant form of urogenital chlamy-15 anti-streptokinase units in 1 ml
диоза.плазмы крови.Diosa. Blood plasma.
При клиническом обследовании: вDuring clinical examination: in
анамнезе мочи следы белка, слизь ++, Курс ферментотерапии авелизиномhistory of urine traces of protein, mucus ++, a course of enzyme therapy avelysin
лейкоциты 2-5-6 в поле зрени ; вназначают в дозе от 5000 до 15000 ME крови активность .антиактиватора плаз- 2о внутривенно капельно в количествеleukocytes 2-5-6 in the field of vision; in a dose of from 5000 to 15000 ME of blood, the activity of plasma anti-activator is administered intravenously in the amount of
миногена снижена до 49% (норма 82±17 вливаний один раз в день. Черезminogen is reduced to 49% (the rate of 82 ± 17 infusions once a day. Through
±1,2% по Беннет), титр антител к7 дней от начала внутривенного влистрептокиназе 25 антистрептокиназныхвани авелизина дополнительно пероедин1Лх в 1 мл плазмы крови.рально назначают эрициклин по 0,25± 1.2% Bennett), antibody titer by 7 days from the start of intravenous anti-streptokinase 25 anti-streptoxase avelysin additionally peroedin1Lh in 1 ml of blood plasma. Erycycline is prescribed orally by 0.25
Назначают курс ферментотерапии 25 четыре раза в день продолжительностьюAssign a course of enzyme therapy 25 four times a day lasting
минимальными дозами стрептокиназы -10 дней, авелизина. Авелизин в дозе 500010 000 ME разбавл ют в 50-100 мл фи- В результате ферментотерапииminimum doses of streptokinase -10 days, avelysin. Avelysin in a dose of 500010 000 ME is diluted in 50-100 ml phi. As a result of enzyme therapy
зиологического раствора, ввод т ка-стрептокиназой в комбинации с антиби- пельно внутривенно в течение 25- зо отикотерапией воспалительные влени saline solution, administered by streptokinase in combination with intravenous antibiotic during 25-day ot-therapy, inflammatory effects
30 мин один раз в день. После 15 вли-в уретре и предстательной железе полваний стрептокиназосодержащего препа-ностью исчезли, рата (авелизина) титр антител к .30 min once a day. After 15, the urethra and prostate gland of polvany of streptokinase-containing pre-dysfaction disappeared, rata (avelysin) antibody titer to.
стрептокиназе повысилс до 300 а.ед. Активность антиактиватора плазмиДополнительно назначают эрициклин пе-ногена повысилась до 53%, титр антирорально по 0,25 г четыре раза в деньстрептокиназы повысилс до 450 а.ед.Streptokinase increased to 300 a.u. The activity of the plasmid antiactivator. In addition, they prescribed erycycline on the penguin increased to 53%, the antiroral titer of 0.25 g four times a day increased streptokinase up to 450 aa.
продолжительностью 10 дней. При этом,Больной выздоровел. Рецидива нет. одновременно продолжают внутривенныеlasting 10 days. At the same time, the patient recovered. No recurrence. simultaneously continue intravenous
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU864079884A SU1342509A1 (en) | 1986-03-18 | 1986-03-18 | Method of treatment of urogenital chlamidioses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU864079884A SU1342509A1 (en) | 1986-03-18 | 1986-03-18 | Method of treatment of urogenital chlamidioses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1342509A1 true SU1342509A1 (en) | 1987-10-07 |
Family
ID=21242285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU864079884A SU1342509A1 (en) | 1986-03-18 | 1986-03-18 | Method of treatment of urogenital chlamidioses |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1342509A1 (en) |
-
1986
- 1986-03-18 SU SU864079884A patent/SU1342509A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Ориэл Дж. Д. и др., Хламидиоз,- М., 1984, с. 27. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barza et al. | Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. | |
| Wilson et al. | Fifteen years' experience with Staphylococcus septicemia in a large city hospital: analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954 | |
| Whiteside et al. | Intrathecal amethopterin in neurological manifestations of leukemia | |
| US7767204B2 (en) | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels | |
| Hunter et al. | Sustained levodopa therapy in parkinsonism | |
| ES2298141T3 (en) | A PHARMACEUTICAL FORMULATION THAT MELAGATRAN AND HIS PROFARMACY UNDERSTAND | |
| Siegal et al. | Antibiotic therapy for infected Ommaya reservoir systems | |
| AU2015212613B2 (en) | Use of cladribine for treating neuromyelitis optica | |
| JPH01500997A (en) | Use of hyaluronidase | |
| Dimopoulos et al. | HyperCVAD for VAD‐resistant multiple myeloma | |
| JPH04503062A (en) | fibrinolysis | |
| King et al. | Therapy with Erwinia L‐asparaginase in children with acute leukemia after anaphylaxis to E. coli L‐asparaginase | |
| SU1342509A1 (en) | Method of treatment of urogenital chlamidioses | |
| EP0278416B1 (en) | Use of human blood coagulation factor xiii for the treatment of ulcerative colitis | |
| Barza | Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics, Part 2: penicillins | |
| US20210330757A1 (en) | Methods and compositions for inducing neural plasticity | |
| Rupp et al. | Central venous catheter-related Corynebacterium minutissimum bacteremia | |
| Crawford et al. | Necrotizing Fasciitis Associated With Haemophilus aphrophilus: Report of a Case | |
| Newman et al. | Small cell lung carcinoma. A phase II evaluation of r‐interferon‐γ | |
| US4585653A (en) | Neuraminidase treated ancrod | |
| CN115282280A (en) | New uses for TGF-β1 signaling inhibitors | |
| RU2649760C1 (en) | Method of treatment of acute myocardial infarction with staging of st segment complicated by cardiogenic shock | |
| JPH0560813B2 (en) | ||
| SU1326265A1 (en) | Method of treatment of ophthalmoherpes | |
| Callaghan et al. | CSF perfusion to treat intraventricular penicillin toxicity |